These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 6937954)

  • 61. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
    Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
    Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Complicated diverticulitis: treatment with cefoxitin sodium.
    Goodpasture HC; Ellis D; Voth DW
    J Kans Med Soc; 1981 Jul; 82(7):349-51, 369. PubMed ID: 7252306
    [No Abstract]   [Full Text] [Related]  

  • 65. [Prospective and comparative study of cefoxitin and ceftizoxime in appendicitis surgery].
    Sanz Villa N; Alvarez Bernaldo de Quirós M; Cortés Gómez MJ; Omeñaca C
    An Esp Pediatr; 1997 Sep; 47(3):279-84. PubMed ID: 9499281
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Resistance to cefamandole: a collaborative study of emerging clinical problems.
    Sanders CC; Moellering RC; Martin RR; Perkins RL; Strike DG; Gootz TD; Sanders WE
    J Infect Dis; 1982 Jan; 145(1):118-25. PubMed ID: 6274965
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Perforated and gangrenous appendicitis: an analysis of antibiotic failures.
    Heseltine PN; Yellin AE; Appleman MD; Gill MA; Chenella FC; Kern JW; Berne TV
    J Infect Dis; 1983 Aug; 148(2):322-9. PubMed ID: 6224864
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-dose cefamandole therapy in obstetric and gynecologic infections.
    Gall SA; Hill GB
    Am J Obstet Gynecol; 1980 Aug; 137(8):914-22. PubMed ID: 7405988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole.
    Shadomy S; Wagner G; Carver M
    Antimicrob Agents Chemother; 1978 Mar; 13(3):412-5. PubMed ID: 400821
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Stability of cefamandole nafate and cefoxitin sodium solutions.
    Das Gupta V; Stewart KR
    Am J Hosp Pharm; 1981 Jun; 38(6):875-9. PubMed ID: 7246563
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activity of cephazolin and other cephalosporins against Bacteroides fragilis.
    Leigh DA; Simmons K
    Scott Med J; 1976 Sep; 20(5):228-31. PubMed ID: 1265472
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds.
    Neu HC
    J Infect Dis; 1978 May; 137 Suppl():S80-S87. PubMed ID: 650006
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Susceptibility of Bacteroides fragilis, Bacteroides thetaiotaomicron, and Fusobacteria in Antibacterial agents.
    Niederau W; Höffler U; Pulverer G
    Arzneimittelforschung; 1980; 30(12):2093-8. PubMed ID: 7194067
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Action of cefoxitin and cefamandole on human neutrophil function.
    Majeski JA; Morris MJ; Alexander JW
    J Antibiot (Tokyo); 1978 Oct; 31(10):1059-62. PubMed ID: 711612
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
    Dunn DL; Rotstein OD; Simmons RL
    Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical experience with cefamandole for treatment of serious bone and joint infections.
    Levine LR; McCain E
    J Infect Dis; 1978 May; 137 Suppl():S119-S124. PubMed ID: 649996
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
    Thadepalli H; Gollapudi SV; Chuah SK
    Antimicrob Agents Chemother; 1986 Oct; 30(4):574-6. PubMed ID: 3539011
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The interaction of glucan and cefoxitin in prevention of murine abscess.
    Hull CC; Stellato TA; Rhodes RS; Galloway P; Hawkins NL
    Curr Surg; 1986; 43(5):416-8. PubMed ID: 3533446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.